Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. operates as a healthcare services fertility company focused on assisted reproductive technology care through the establishment, acquisition and operation of fertility clinics and related technologies. Company news commonly covers clinic expansion, acquired fertility practices, network relationships, laboratory capabilities and the use of the INVOcell medical device for intravaginal culture procedures.
Recurring updates also include intellectual-property developments for INVOcell, operational changes at U.S. fertility clinics, capital-structure actions such as reverse stock splits, shareholder communications, securities-listing compliance matters and financial-reporting status. Recent company materials also identify Family Beginnings and Wisconsin Fertility Institute as part of the clinic platform.
INVO Fertility reported strong financial results for 2024, achieving a remarkable 116% annual revenue growth to $6.5 million. The company's Q4 2024 revenue reached $1.69 million, up 22% year-over-year.
Key highlights include a 125% increase in consolidated clinic revenue to $6.45 million and a 78% rise in total clinic revenue to $7.73 million. Despite these gains, the company recorded a net loss of $9.1 million, largely due to NAYA Therapeutics merger costs. However, Adjusted EBITDA improved significantly to $(2.2) million from $(4.9) million in 2023.
The company announced plans to divest its majority stake in NAYA Therapeutics to refocus on its core fertility operations. With three operating fertility centers in Wisconsin, Georgia, and Alabama, INVO aims to expand into additional markets, capitalizing on declining U.S. fertility rates and increasing demand for assisted reproductive technologies.